Novartis Finance S.A. EO-Notes 2017(17/27)
- BID
98.121
- ASK
98.295
- 550,000 Nom.550,000 Nom.
- 07/27, 19:03:36 PM
Type of financial instrument
Corporate Bond
Sub-Type
Health Care
Yield
2.78
Yield spread Bundesanleihe
0.0484
Tradable for private investors
No
Minimum amount tradeable unit
100,000.00
Maturity
30/09/2027
Interest Rate
1.125 %
Currency
Euro
Facts & figures
Price data
| TRADE PLATFORM | Börse Stuttgart (XSTU) | |
| LAST PRICE / YIELD | 98.121 G / 2.78 | 0 Units |
| PRICE DETERMINATION TIME | 07/27/2026 / 07:03:36 PM | |
| DAILY VOLUME (NOMINAL) | 0 | |
| YIELD SPREAD | 0.0484 | |
| FIXINGPRICE | - | |
| DAILY HIGH / LOW | 98.121 | 98.096 |
| PREV. DAY'S PRICE | 98.111 | (07/24) |
| CHANGE DAY BEFORE | +0.01 | 0.01 % |
| 52 WEEK HIGH / LOW | 98.356 (02/02) | 97.312 (03/23) |
Master Data
| WKN | A19FG5 |
| ISIN | XS1585010074 |
| SYMBOL | NOJA |
| EXCHANGE SEGMENT | Freiverkehr |
| TYPE OF FINANCIAL INSTRUMENT | Corporate Bond |
| SUB-TYPE | Health Care |
| ISSUER | Novartis Finance S.A. |
| S&P RATING | Please log in to view this field |
| (TRADING) SEGMENT / TICKS | -/ - |
| TRADING HOURS | 07:30:00 AM - 10:00:00 PM |
| INTEREST RATE | 1.125 % |
| INTEREST RUN FROM | 31/03/2017 |
| NEXT INTEREST PAYMENT | 30/09/2026 |
| UNIT INTEREST FROM NOMINAL AMMOUNT | 0.931 % |
| TRADING CURRENCY / NOTATION | Euro/ Percent |
| NOMINAL CURRENCY | Euro |
| SETTLEMENT CURRENCY | Euro |
| QUOTATION | Continuous trading |
| ISSUING VOLUME | 600.00 Mil. |
| MINIMUM AMOUNT TRADEABLE UNIT | 100,000.00 |
| SMALLEST TRADEABLE UNIT | 1,000.00 |
| MATURITY | 30/09/2027 |
| MARKET MAKER | - |
| STEP UP/ DOWN WHEN RATING CHANGES | No |
| STEP UP FIXED AT ISSUE | No |
| STEP DOWN FIXED AT ISSUE | No |
| BOND CALLABLE BY THE ISSUER | Yes |
| BOND IS SUBORDINATED | No |
Description
Make Whole Call Option. Callable bond.
Tradability Information
Please log in to see the tradability information for this stock.Not registered yet? Create your free account here.
Company profile
Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. Its product portfolio is heavily focused on innovative prescription medicines, especially oncology, immunology, neuroscience, and cardiovascular diseases, supplemented by established older brands and a wide range of specialized therapies. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.